AU2001259441A1 - Cellular regulators of infectious agents and methods of use - Google Patents

Cellular regulators of infectious agents and methods of use

Info

Publication number
AU2001259441A1
AU2001259441A1 AU2001259441A AU5944101A AU2001259441A1 AU 2001259441 A1 AU2001259441 A1 AU 2001259441A1 AU 2001259441 A AU2001259441 A AU 2001259441A AU 5944101 A AU5944101 A AU 5944101A AU 2001259441 A1 AU2001259441 A1 AU 2001259441A1
Authority
AU
Australia
Prior art keywords
methods
infectious agents
cellular regulators
regulators
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259441A
Inventor
Jack R. Barber
Martin Kruger
Peter J. Welch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immusol Inc
Original Assignee
Immusol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc filed Critical Immusol Inc
Publication of AU2001259441A1 publication Critical patent/AU2001259441A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001259441A 2000-05-02 2001-05-02 Cellular regulators of infectious agents and methods of use Abandoned AU2001259441A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/563,794 2000-05-02
US09/563,794 US6808876B1 (en) 2000-05-02 2000-05-02 Cellular regulators of infectious agents and methods of use
PCT/US2001/014337 WO2001083754A2 (en) 2000-05-02 2001-05-02 Cellular regulators of infectious agents and methods of use

Publications (1)

Publication Number Publication Date
AU2001259441A1 true AU2001259441A1 (en) 2001-11-12

Family

ID=24251923

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259441A Abandoned AU2001259441A1 (en) 2000-05-02 2001-05-02 Cellular regulators of infectious agents and methods of use

Country Status (5)

Country Link
US (2) US6808876B1 (en)
EP (1) EP1278845A2 (en)
AU (1) AU2001259441A1 (en)
CA (1) CA2409219A1 (en)
WO (1) WO2001083754A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824072B1 (en) * 2001-04-27 2004-03-12 Centre Nat Rech Scient PROCESS FOR REPLICATION AND PRODUCTION OF HEPATITIS C VIRUS
JP2006500012A (en) * 2002-07-31 2006-01-05 ヌクレオニクス インコーポレーティッド Structures and constructs of double-stranded RNA, and methods for producing and using the same
CA2506619A1 (en) 2002-11-18 2004-08-19 Thomas W. Hodge Cell lines and host nucleic acid sequences related to infectious disease
WO2005071101A1 (en) * 2004-01-23 2005-08-04 University Hospital Of Basel Treatment of hepatitis c infection by increasing stat1 methylation
US20090247455A1 (en) * 2005-03-31 2009-10-01 Mark Fear Isolation of Inhibitors of IRES-Mediated Translation
US7598040B2 (en) 2006-11-22 2009-10-06 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
US20100291032A1 (en) * 2007-09-14 2010-11-18 Trana Discovery Compositions and methods for the identification of inhibitors of retroviral infection
WO2010036795A2 (en) * 2008-09-29 2010-04-01 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
CA2087519C (en) 1990-07-16 2002-10-22 Fred Russell Kramer Selection of ribozymes that efficiently cleave target rna
US5496698A (en) 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc Method and reagent for inhibiting viral replication.
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
DE69430665T2 (en) 1993-01-15 2002-11-21 New York Health Res Inst SENSITIVE NUCLEIC ACID SANDWICH HYBRIDIZATION ASSAY AND KITS
CN1127527A (en) 1993-05-17 1996-07-24 加利福尼亚大学董事会 Ribozyme gene therapy for HIV infection and Aids
US5580967A (en) 1994-05-13 1996-12-03 The Scripps Research Institute Optimized catalytic DNA-cleaving ribozymes
DE4424762C1 (en) 1994-07-04 1995-07-27 Max Planck Gesellschaft Ribozyme library in optimised expression cassette
CA2278734A1 (en) 1997-01-23 1998-07-30 Immusol Incorporated Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries
WO2000005415A1 (en) 1998-07-22 2000-02-03 Immusol Incorporated Substantially complete ribozyme libraries
WO2000011171A2 (en) 1998-08-21 2000-03-02 Incyte Pharmaceuticals, Inc. Human rna-associated proteins
WO2000058473A2 (en) 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
WO2001055355A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Also Published As

Publication number Publication date
US6808876B1 (en) 2004-10-26
CA2409219A1 (en) 2001-11-08
WO2001083754A2 (en) 2001-11-08
WO2001083754A3 (en) 2002-10-03
EP1278845A2 (en) 2003-01-29
US20050064396A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
AU2002314466A1 (en) Withasol and methods of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002324775A1 (en) Architecture tool and methods of use
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2002211389A1 (en) Microfluidic devices and methods of use
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
AU2002257325A1 (en) Cleavable surfactants and methods of use thereof
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2002359512A1 (en) Belts and methods of use thereof
AU2001273074A1 (en) Combinations of ssri and estrogenic agents
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2001288972A1 (en) Antipsychotic sulfonamide-heterocycles, and methods of use thereof
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2001273052A1 (en) Antifungal compounds and methods of use
AU2001259441A1 (en) Cellular regulators of infectious agents and methods of use
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2002310237A1 (en) Sponge-derived terpenoids and methods of use
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
EP1263935A4 (en) Scytonemin and methods of using thereof
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AUPQ760400A0 (en) Herbical formulations and methods of use thereof
AU2001234180A1 (en) Benzamide derivative and use thereof
AU3863900A (en) Prolyl peptidases and methods of use